ATRC Stock Overview
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AtriCure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.14 |
| 52 Week High | US$59.61 |
| 52 Week Low | US$32.27 |
| Beta | 1.35 |
| 1 Month Change | -3.75% |
| 3 Month Change | -17.95% |
| 1 Year Change | -19.75% |
| 3 Year Change | -27.16% |
| 5 Year Change | 15.85% |
| Change since IPO | 142.47% |
Recent News & Updates
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Nov 29
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Sep 27Recent updates
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Nov 29AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Sep 27Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Aug 02AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion
Jun 15Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Apr 14Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)
Mar 02What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?
Feb 09Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Dec 28Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?
Sep 06An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued
Aug 02AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks
Jun 13Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Jun 08Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
May 08Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 11Is AtriCure (NASDAQ:ATRC) A Risky Investment?
Feb 18Why AtriCure, Inc. (NASDAQ:ATRC) Could Be Worth Watching
Jan 20Robust Earnings May Not Tell The Whole Story For AtriCure (NASDAQ:ATRC)
Nov 11Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Oct 21Shareholder Returns
| ATRC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.6% | -0.5% | 0.2% |
| 1Y | -19.7% | -1.1% | 15.9% |
Return vs Industry: ATRC underperformed the US Medical Equipment industry which returned -1.6% over the past year.
Return vs Market: ATRC underperformed the US Market which returned 14.4% over the past year.
Price Volatility
| ATRC volatility | |
|---|---|
| ATRC Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ATRC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ATRC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,050 | Mike Carrel | https://www.atricure.com |
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes.
AtriCure, Inc. Fundamentals Summary
| ATRC fundamental statistics | |
|---|---|
| Market Cap | US$1.58b |
| Earnings (TTM) | -US$24.82m |
| Revenue (TTM) | US$380.73m |
4.2x
P/S Ratio-65.2x
P/E RatioIs ATRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRC income statement (TTM) | |
|---|---|
| Revenue | US$380.73m |
| Cost of Revenue | US$95.06m |
| Gross Profit | US$285.67m |
| Other Expenses | US$310.49m |
| Earnings | -US$24.82m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 75.03% |
| Net Profit Margin | -6.52% |
| Debt/Equity Ratio | 13.1% |
How did ATRC perform over the long term?
See historical performance and comparison